Clinical Trial: Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07601425) titled 'Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)' on May 12.

Brief Summary: This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601. Patients completing Part 1 may participate in the Part 2 open-label extension to receive ATV-1601.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Hereditary Hemorrhagic Telangiectasia (HHT) Osler Weber Rendu Disease

Intervention: DRUG: ATV-1601

Administered orally, daily

DRUG: Placebo

Administered orally...